Ergothioneine: The Mushroom Thiol Quietly Climbing the Healthspan Charts

Ergothioneine has been on the longevity watch-list for over a decade, largely on circumstantial evidence: humans express a transporter (OCTN1/SLC22A4) that seems specifically built to ferry it into cells, and tissue levels decline with age and certain chronic diseases. That is suggestive, not dispositive. A transporter tells you the body bothers; it doesn't tell you why.

The new work, led by Milos Filipovic's group and published in Cell Metabolism, attempts to answer the why. In a series of experiments spanning C. elegans and aged rats, ergothioneine extended worm lifespan, improved mobility, and reduced several age-associated biomarkers. In rats, supplementation was associated with greater exercise endurance, increased muscle mass, improved muscle vascularization, and higher NAD+ levels in muscle tissue.

The interesting part isn't the endpoints — plenty of compounds extend worm lifespan — it's that the authors traced a chain of causation. Ergothioneine, they report, serves as an alternative substrate for cystathionine gamma-lyase (CSE), an enzyme better known for producing hydrogen sulfide (H₂S). That H₂S then modifies cysteine residues on more than 300 proteins through a process called persulfidation — essentially a sulfur-based post-translational switch. One of those targets, cytosolic glycerol-3-phosphate dehydrogenase (cGPDH), gets activated by persulfidation and appears to account for most of the NAD+ bump observed in muscle.

The proof-of-mechanism is the part that should make even skeptical readers sit up: in animals lacking either CSE or cGPDH, ergothioneine's effects disappeared. That is the kind of causal scaffolding mechanism papers are supposed to provide, and it is largely what this one delivers.

It is not a human trial. It is not evidence that taking an ergothioneine capsule will make you live longer, run farther, or rebuild aging muscle. The leap from C. elegans to a 45-year-old at a desk is, to put it gently, considerable; the leap from aged rats is shorter but still real. Rodent muscle physiology is informative, not predictive. NAD+ in particular has a long résumé of preclinical promise that has translated unevenly into human benefit, and the field has been burned before by extrapolating endurance gains from rodent treadmills to the human gym.

It is also worth naming what the study does not address: optimal dose, duration, bioavailability differences between food and supplement forms, long-term safety in humans, and interactions with the medications and conditions that actually populate the lives of the people most interested in "healthspan." Those are not nitpicks. They are the questions a clinician would ask before recommending anything.

Here is where the story gets boringly sensible. Ergothioneine is concentrated in fungi, and humans get essentially all of theirs from the diet. Eating more mushrooms — especially the specialty varieties — is a low-risk, high-upside move whether or not the longevity claims hold up, because the rest of what mushrooms bring to a plate (fiber, B vitamins, a tidy umami substitute for some of the salt and fat in a dish) is well-established on its own merits. You do not need a mechanism paper to justify a sautéed king trumpet.

Capsules are a different conversation. The supplement industry has moved faster than the evidence, as it tends to, and ergothioneine products now sit on shelves with marketing copy that runs well ahead of what a single preclinical study can support. The mechanism is real and interesting. The human outcome data are not yet there.

The honest answer for any preclinical finding this interesting is: a well-designed human trial. Specifically, randomized, placebo-controlled work in older adults measuring the things this paper actually moved in animals — muscle endurance, lean mass, and tissue NAD+ — with a dose rationale, a duration long enough to matter, and safety monitoring. Until that exists, ergothioneine sits in the same category as several other plausible-and-unproven aging compounds: worth watching, not worth overstating.

It is, on the merits, one of the more credible entries on that list. The transporter is real. The dietary source is benign. The mechanism is now mapped. That is a better starting position than most. It is still a starting position.